Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Insmed Inc’s stock clocked out at $161.81, down -0.31% from its previous closing price of $162.32. In other words, the price has decreased by -$0.31 from its previous closing price. On the day, 1.87 million shares were traded. INSM stock price reached its highest trading level at $163.22 during the session, while it also had its lowest trading level at $159.78.
Ratios:
To gain a deeper understanding of INSM’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.33 and its Current Ratio is at 6.68. In the meantime, Its Debt-to-Equity ratio is 0.59 whereas as Long-Term Debt/Eq ratio is at 0.59.
On August 13, 2025, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight but kept the price unchanged to $126.
On May 13, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $105.Jefferies initiated its Buy rating on May 13, 2025, with a $105 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 12 ’25 when Schaeffer Orlov S Nicole sold 76,520 shares for $145.45 per share. The transaction valued at 11,129,927 led to the insider holds 36,461 shares of the business.
SHAROKY MELVIN MD sold 10,000 shares of INSM for $1,453,900 on Sep 12 ’25. The Director now owns 262,675 shares after completing the transaction at $145.39 per share. On Sep 12 ’25, another insider, Schaeffer Orlov S Nicole, who serves as the Officer of the company, bought 76,520 shares for $145.42 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INSM now has a Market Capitalization of 34202552320 and an Enterprise Value of 33084831744. For the stock, the TTM Price-to-Sale (P/S) ratio is 85.91 while its Price-to-Book (P/B) ratio in mrq is 27.33. Its current Enterprise Value per Revenue stands at 83.106 whereas that against EBITDA is -36.061.
Stock Price History:
The Beta on a monthly basis for INSM is 1.03, which has changed by 1.2567644 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, INSM has reached a high of $162.44, while it has fallen to a 52-week low of $60.40. The 50-Day Moving Average of the stock is 19.64%, while the 200-Day Moving Average is calculated to be 73.34%.
Shares Statistics:
It appears that INSM traded 2.56M shares on average per day over the past three months and 2189390 shares per day over the past ten days. A total of 211.11M shares are outstanding, with a floating share count of 207.27M. Insiders hold about 1.94% of the company’s shares, while institutions hold 99.35% stake in the company. Shares short for INSM as of 1757894400 were 10575467 with a Short Ratio of 4.13, compared to 1755216000 on 10496754. Therefore, it implies a Short% of Shares Outstanding of 10575467 and a Short% of Float of 5.54.
Earnings Estimates
The company has 13.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$1.14, with high estimates of -$0.93 and low estimates of -$1.41.
Analysts are recommending an EPS of between -$5.29 and -$5.91 for the fiscal current year, implying an average EPS of -$5.54. EPS for the following year is -$3.57, with 12.0 analysts recommending between -$2.37 and -$4.87.
Revenue Estimates
In. The current quarter, 17 analysts expect revenue to total $114.9M. It ranges from a high estimate of $121.97M to a low estimate of $106M. As of. The current estimate, Insmed Inc’s year-ago sales were $93.42MFor the next quarter, 17 analysts are estimating revenue of $156.19M. There is a high estimate of $176.11M for the next quarter, whereas the lowest estimate is $135M.
A total of 18 analysts have provided revenue estimates for INSM’s current fiscal year. The highest revenue estimate was $498.14M, while the lowest revenue estimate was $446M, resulting in an average revenue estimate of $472.09M. In the same quarter a year ago, actual revenue was $363.71MBased on 16 analysts’ estimates, the company’s revenue will be $1.07B in the next fiscal year. The high estimate is $1.31B and the low estimate is $900.2M.
